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Though Japan has surpassed South Korea in terms of research and development (R&D) in the area of 
regenerative  medicine,  South  Korea  has  been  more  successful  at  commercialization.  This  paper 
focuses on the setup and operation of actual systems that consider the promotion of regenerative 
medicine in Japan. Analysis of the regulatory systems in Japan and South Korea shows a clear 
difference between the two countries, although their systems are basically the same. There are two 
pathways for applying unapproved drugs in clinical research, including regenerative medicine, to 
human subjects in Japan, whereas there is only one pathway in South Korea, where the Korea Food 
and Drug Administration (KFDA) is the only authority through which approval can be obtained. 
Japan has an additional pathway besides approval through the Pharmaceuticals and Medical Devices 
Agency  (PMDA),  if  the  clinical  research  is  conducted  within  the  framework  of  the  Medical 
Practitioners Law. 
 
The authors assume that the coexistence of the two pathways in Japan creates inefficiencies 
in  commercializing  regenerative  medicine  products  (RMPs).  Therefore,  to  disseminate 
regenerative medicine in Japan, the authors recommend combining the two pathways under 
PMDA authority. 
 
RIETI Discussion Papers Series aims at widely disseminating research results in the form of professional 
papers,  thereby stimulating lively discussion. The views expressed in the papers are solely those of the 
author(s), and do not represent those of the Research Institute of Economy, Trade and Industry. 2 / 27 
   
1.  Introduction 
 
Expectations  for  regenerative  medicine  are  broadly  expanding  together  with  public  desire  for 
improved health and amid rapid development in related disciplines. To fulfill these expectations, a 
number of policy steps have been taken in Japan since around 2000 to promote research related to 
regenerative  medicine.  The  question  becomes  whether  these  policies  can  effectively  achieve 
commercialization  of  regenerative  medicine.  Another  question  is  whether  public  welfare  will 
improve as a result of such commercialization. 
 
To answer these questions, this paper examines a variety of literature to reveal the present status of 
commercialization in Japan in comparison with the rest of the world. Based on the results, it is 
estimated that in the research phase considerable achievements have been made in Japan. However, 
in terms of practical application of the research output, relatively little progress has been made. The 
emergence of regenerative medicine is clearly lagging in Japan in comparison to developments in 
other major global economies. 
 
The complexity of introducing and establishing new technology in society can help explain this 
situation. A number of factors are intertwined in commercializing technology, and it is difficult to 
differentiate  them.  From  an  industrialization  viewpoint,  for  instance,  the  social  circumstances 
affecting business activities are key
1. This point must be taken consideration not only in the case of 
regenerative medicine but for any new technology. 
 
Regenerative medicine, on the other hand, as its name indicates, will be used in society as a medical 
technology.  This  means  that the technology is commercialized under the regulatory regime that 
governs the medical field. This paper focuses on Japan’s regulations in the medical field from the 
perspective of promoting the commercialization of regenerative medicine. Tremendous regulatory 
disparities  exist  between  Japan  and  other  major  economies.  Based  on  this,  the  current  state  of 
commercialization in regenerative medicine is considered by referring an actual case of approval 
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2.  Progress of Regenerative Medicine 
 
2.1.  Transplantation of Biological Function 
 
A healthier and longer life is probably the desire of every person at any time in any place in the 
world. Life expectancy in Japan today has extended significantly, and for the desire of people to 
enjoy fulfilling lives in good health are growing in step with the extension of their life span. 
 
Responding to these expectations, medical care has achieved remarkable progress. New treatments 
for diseases once considered incurable have been found as a result of aggressive research, and have 
been applied in numerous medical fields. Regenerative medicine, the subject of this paper, is one 
such treatment. Through the human body’s self-renewal abilities a lost function can be restored. 
Regenerative medicine, in this context, can be seen as an ultimate therapy. 
 
The self-renewal capability of animals has been known since ancient times. The first case for the use 
of  this  capability  in  humans  was  bone  marrow  transplantation,  which  grants  a  hematopoietic 
biological function. The first human bone marrow transplant was performed in 1957, and in 1974, 
the  world’s  first  bone  marrow  bank  was  established  in  the  United  Kingdom.  Since  then,  bone 
marrow transplants have been performed many times around the world. The world’s first cord blood 
transplant was performed in 1988 as the same therapy, and the first cord blood bank was established 
in the United States in 1993. 
 
Bone marrow transplantation is actually the transplantation of the hematopoietic stem cell itself, 
which is contained within the bone marrow. In contrast, new treatments are emerging in which 
tissues rather than cells are transplanted. Tissues are formed from cells on which biochemical or 
physicochemical operations are conducted; a field of technology called tissue engineering
2, which 
has been a highly active area in recent years. 
 
One example of efforts in this area is for the skin. Green et al. in 1975 developed a culture method 
for the epidermis
3, and in 1981 autologous transplantation of epidermis was successful for burn 
patients using this technology
4. Bell et al. in 1981 developed cultured skin cells with allogeneic 
cells
5,6, and in 1994, Brittberg et al. reported autologous transplantation of cultured chondrocytes
7. A 
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number of clinical cases have been reported up to the present. 
 
 
2.2.  Rapid Development − Technology in Infancy 
 
The development of basic research on stem cells such as hematopoietic, neural, and mesenchymal 
stem cells has played a key role in the development of regenerative medicine shown in the previous 
subsection. The studies have helped enhance basic knowledge on biological processes such as cell 
differentiation and development of individuals, tissues, and cells. In the background of this research 
are also advances in technologies for efficient cell culture and separation. 
 
A series of innovative research results have been produced in addition to these advances in basic 
research. An embryonic stem cell was established from a mouse in 1981
8,9, a primate in 1995
10  and 
finally a human in 1998
11. The most relevant achievement recently in this field concerns the induced 
pluripotent stem (iPS) cell, which was established from a mouse in 2006
12  and a human in 2007
13,14. 
 
Scientific knowledge on regenerative medicine continues to move forward with strong momentum. 
The technology is also finding practical application with the advancement of scientific outcomes. In 
a country or region where there is only a small body of research, with the rapid development stage in 
academia concentrated research activities make it possible to improve scientific output to a certain 
level.  Developing  practical  applications  for  the  outcomes,  is  somewhat  easier  in  regenerative 
medicine as opposed to, say, aerospace in which massive systemized technologies are required, or 
industrial machinery, which requires extensive integration of industries. 
 
In this context, by concentrating resources, regenerative medicine can be commercialized relatively 
easily in a  country or region  with a  national financial foundation,  even without sufficient large 
accumulation of basic research. These are the characteristics that mark regenerative medicine. In 
response to these technical characteristics, a great deal of research has been conducted around the 
world with the aim of commercializing regenerative medicine. 
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2.3.  Form of Dissemination – Supply to the Market as a Product 
 
Transplanting human cells with a low degree of processing, such as bone marrow transplantation and 
cord  blood  transplantation,  has  been  performed  within  clinical  organizations  as  part  of  medical 
treatment. Transplantations of highly processed human cells, however, have not been able to be 
completed  only  within  clinical  organizations.  Tissue  engineering  is  a  typical  case.  Autologous 
cultured epidermis, considered to be the first effort to commercialize regenerative medicine by tissue 
engineering, has been provided since 1988 to clinical organizations under the product name Epicel, 
by Genzyme Corporation. 
 
As seen in this example, full dissemination of regenerative medicine beyond the area of a clinical 
research is usually achieved by a corporation that supplies a regenerative medicine product (RMP), a 
product made from human cells processed for efficacy in treatment. This requires an industry for 
supplying RMPs. Regenerative medicine is a “medical” treatment approach, as referred to in its 
name, yet the  style of dissemination is the  product  launch in  the market, which is close to the 
development of pharmaceuticals and medical devices. 
 
In the manufacturing and sale of pharmaceuticals and medical devices, a certain approval is required 
based on a review of efficacy and safety by each regulatory authority in each country or region. For 
the production and sale of regenerative medicine, regulations were not clear on whether an approval 
was required in the early days of their introduction, since regenerative medicine differs significantly 
from conventional pharmaceuticals and medical devices
15. At present, RMPs must receive approval 
under a category such as pharmaceuticals or medical devices before they can be manufactured and 
sold. The national regulatory system has largely converged on this concept. 
 
Reviews for approval of efficacy and safety are conducted based on data obtained from clinical trials 
in which pharmaceuticals or medical devices under review are used on humans. Even in testing, 
unapproved drugs are administered to humans in clinical trials. Therefore, the clinical trial itself is 
under the review and approval is required, otherwise it cannot be conducted. 
 
 
2.4.  Pathway for Dissemination 
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In  addition  to  regulation  on  efficacy  and  safety,  a  government-set  pricing  system  has  been 
introduced for pharmaceuticals, etc. instead of pricing under the market mechanism used in most 
developed  countries
16.  This  requires  a  public  medical  insurance  system  that  covers  the  entire 
population.  In  the  presence  of  such  a  system,  the  price  of  pharmaceuticals  is  subject  to  policy 
decisions on setting the amount that insurance will pay. Such systems are deeply rooted in society 
and have a strong impact on the introduction of related technology to society. 
 
The regulation and pricing stages mentioned above must be passed through in order to disseminate 
regenerative medicine in society with the launch of RMPs. Figure 1 shows the pathway for the 
dissemination of regenerative medicine. Each stage of this flow is in a series, and all stages are 
necessary for dissemination. 
 
 




3.  Present Situation in Japan 
 
3.1.  Effort in Japan – A Policy Issue 
 
In Japan, a policy approach to promoting the commercialization of regenerative medicine has been 
actively  underway  since  around  2000,  amid  growing  interest  based  on  the  growth  of  scientific 
knowledge  to  enable  its  practical  application.  From  the  perspective  of  promoting  research  at 
universities, the Institute for Frontier Medical Sciences was established at Kyoto University in 1998 
with the purpose of studying and its applications for the regeneration of living tissues and organs. 
The  institute  is  the  first  established  research  organization  in  Japan  specializing  in  regenerative 
medicine. 
 
At the Ministry of Health, Labour and Welfare (MHLW), which regulates medical affairs in Japan, a 
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commitment to regenerative medicine was being actively promoted at the time. A report titled “The 
Future Way of the Study in the Health and Welfare Science for the 21st Century” was compiled by 
the  MHLW’s  Health  Science  Council  in  November  1999.  The  report  states  that  “so-called 
regenerative medicine, which may enable repair of damaged areas of the body and dysfunctional 
organs by using one’s own or donated tissues and organs, is an anticipated form of treatment and its 
development will be advocated.” In response to the report, a new category for regenerative medicine 
was set up in 2000 under a Health Labour Sciences Research Grant, one of the most common grants 
in the medical field. 
 
For government as a whole, promotion of regenerative medicine has come to be a main policy issue. 
On  the  occasion  of  the  new  millennium  in  2000,  the  Japanese  government  established  the 
“Millennium  Project,”  a  policy  package  with  the  justification  that:  “in  response  to  challenges 
humans  are  facing,  we  will  undertake  technological  innovation  for  creating  new  industries.” 
Promotion of regenerative medicine is advocated within this. Specifically it states that “regenerative 
medicine  for  bones  and  blood  vessels  will  be  achieved  using  self-regeneration  ability  without 
rejection based on elucidation of biological functions such as generation.”
17 
 
The BT Strategy Council was also set up by the Prime Minister in July 2002 from a standpoint of 
“strengthening  industrial  competitiveness  and  improving  people’s  lives  by  industrializing  and 
commercializing  the  remarkable  achievements  of  biotechnology.”
18   “Biotechnology  Strategy 
Outline,”
19  compiled by the Council in December 2002, states  that  the direction is  “toward the 
realization of regenerative medicine to promote research for the regeneration of organs along with 
elucidation of the mechanism for generation and regeneration.” 
 
A certain governmental budget has been allocated to various kinds of R&D projects via the MHLW, 
the  Ministry  of  Education,  Science  and  Technology  and  the  Ministry  of  Economy,  Trade  and 
Industry under these government policies. 
 
 
3.2.  Research Results - Numbers of Papers 
 
As shown in the previous subsection, the promotion of regenerative medicine has been raised as a 
government-level challenge in Japan, and related research has been promoted for its realization. The 
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question  is  then  raised  as  to  how  the  results  of  these  efforts  should  be  evaluated.  From  this 
perspective, the situation of the world’s research on regenerative medicine was examined via trends 
of papers in this field. The Japan Patent Office (JPO) in 2009 conducted a detailed study on the 
world’s research and patents on regenerative medicine
20. The following is analysis, based on the JPO 
survey
21, of research papers published during 2004-2007 related to regenerative medicine. 
 
Figure 2 shows the number of papers per country or region of the research institute to which each 
paper’s lead author belongs. The United States is first, with 2,304 of 7,472 papers, or 31%. Europe
22 
is second with 2,223 (30%). Japan is third with 1,058 (14%). 
 
 
Source: Based on data from JPO (2009) 
Fig. 2    Number of Papers on Regenerative Medicine (2004-2007) 
 
Regarding the contents of the papers, regenerative medicine-related technology is broadly divided 
into  three  categories  of  basic  technology,  applied  technology  and  supporting  technology.  Basic 
technology  is  a  technique  for  manipulating  cells  that  is  critical  and  fundamental  for  realizing 
regenerative  medicine.  This  category  specifically  consists  of  techniques  such  as  separation, 
purification,  cultivation,  growth,  differentiation,  modification  and  preservation  of  cells  and  the 
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technology of related equipment. 
 
Applied  technology  refers  to  technologies  such  as  transplantation  of  cells  and  scaffolds, 
administration  of  the  inducer  and  the  combination  of  these,  and  the  formulation  of  functional 
structures by using cells in vitro and its utilization for medical treatment; technologies assumed to 
apply  practically  for  humans.  Supporting  technology  is  for  implementing  regenerative  medicine 
safely and effectively; consisting of packaging, transport, safety evaluation and quality control for 
therapeutic cells, as well as industrial cell culture systems. Figure 3 shows the numbers of published 
papers by technology category. 
 
 
Source: Based on data from JPO (2009) 
Fig. 3    Papers by Ratio of Technology Category 
 
Looking  at  the  context  of  the  research  phase  of  these  three  classifications,  basic  technology 
corresponds to the basic and non-clinical research stage. Clinical research is included in applied 
technology. Research required in the commercialization stage can be considered to correspond to 
supporting technology. There is no extreme difference in the proportions of each category among 
country or region, but the United States and Europe have a greater ratio of supporting technology. 
Japan is characterized by a large proportion of applied research. 
 
 
3.3.  Status of Products Launched 
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research. The situation can be estimated from the number of RMPs on the market. A current view of 
the entire world shows that only three kinds of RMP (skin, cartilage, and bone) organized from cells 
by tissue engineering have been identified in the market. The number of RMPs on the market is 
shown in Table 1 by the developers’ country or region. 
 
Regenerative medicine has been practiced in various ways such as not only transplanting cells as a 
form of tissue or organ but also transplanting them as a form of the cells themselves. Cells are thus 
also considered a kind of RMP
23  even though they are not organized as a form of tissue or organ. 
The status of the use of RPMs including this kind is difficult to grasp clearly since some are not used 
as marketed products but instead used as in-house processed materials. For this reason, RMPs shown 
in Table 1 exclude products as a form of cells. 
 
Table 1    Number of RMPs Launched 
  USA  Europe  Japan 
South 
Korea 
Others  Total 
Skin  5  4  1  4  2  16 
Cartilage 
and bone 
1  12  -  3  1  17 
Total  6  16  1  7  3  33 
Note 1: As of December 2009 
Note 2: RMPs shown in the table are limited to those organized as a form of tissue or organ by using tissue 
engineering. 
Note 3: Companies with multiple nationalities are categorized according to the nation in which the major 
development was carried out. 
Source: Created by the authors based on data from company homepages, Mitsubishi Chemical 
Techno-Research Corporation (2009), Korean Ministry of Education, Science and Technology (2009), 
etc. 
 
Comparing  the  situation  shown  in  Table  1  with  the  research  output  described  in  the  previous 
subsection, it is understandable that the volume of research conducted on supporting technology is 
far less than research done on basic and applied technologies. This is because regenerative medicine 
has not been fully introduced yet, but anticipation is growing. Research on supporting technology is 
mainly done in the United States and Europe, which can be understood as a result of the introduction 
of regenerative medicine proceeding at a faster pace in those regions. 
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While holding the fifth position in research output, South Korea is noteworthy for its number of 
marketed RMPs. From a considerable volume of research conducted in South Korea, as shown in 
Figure 2, it is reasonable to anticipate that a certain number of products will be launched; however, it 
is hardly possible to anticipate the actual number. On the other hand, Japan is quite the opposite with 
only one RMP marketed despite holding third position in terms of research output. 
 
 
3.4.  Japan’s Situation in Detail 
 
As shown above, just one RMP has been launched in Japan, which is strikingly low relative to the 
amount of research being done. In the dissemination pathway shown in Figure 1, this situation 
means the uppermost flow of the research stage is heavy but the lower flow of the market approval 
stage is light. The question is then, what is happening in the clinical trial stage, which is located 
between  the  two  stages?  This  subsection  considers  Japan’s  situation  in  the  dissemination  of 
regenerative medicine from this perspective. 
 
South Korea appears similar to Japan in terms of promoting research, following after the US and 
Europe. As described above, a great deal of research has been conducted and many RMPs have been 
launched recently in South Korea. It is helpful to compare Japan and South Korea to deepening the 
understanding of Japan’s situation. 
 
In both Japan and South Korea, RMPs are not allowed to manufacture or sell unless approved by the 
regulatory authority. Table 1 shows the status of market approval for RMPs in the two countries. 
Autologous cultured skin by Japan Tissue Engineering Co.,, Ltd. (J-TEC) is the only case of an RMP 
approved  in  Japan.  In  contrast,  three  companies  have  launched  four  RMPs  in  skin  and  two 
companies with three RMPs in cartilage and bone in South Korea. This means five companies have 
received market approval for seven products. In terms of an RMP as a form of cell itself, which is 
excluded in Table 1, no product has yet been approved in Japan while five have been approved in 
South Korea. Most of the approved products in this form mainly involve activated lymphocyte for 
cancer treatment. 
 
Market approval is supposed to be given based on the authority’s review, in which data obtained 
from clinical trials must be used. The discussion then becomes the situation of clinical trials. Table 2 
shows clinical trials on RMPs in Japan and South Korea, including products in the forms of not only 
tissues or organs, but also cells themselves. Here we see a much greater difference between the 12 / 27 
 
countries than with market approval. 
   
The launch of RMPs must proceed through the stages shown in Figure 1. The commercialization of 
regenerative medicine, therefore, is highly dependent on how many products or product candidates 
are on this track. There are only few candidates at the clinical trial stage in Japan, which seems to 
contradict the current state of research being conducted. Given that the pathway is a series, it is 
possible to say that the low number of market approvals is caused by the low number of clinical 
trials. This situation has become prominent in Japan when compared to South Korea, for which the 
absolute amount of research has  been greatly surpassed by Japan. This situation thus raises the 
question of what exactly is going on. 
 
Table 2    Clinical Trials in Japan and South Korea 
Phase  I/II  III  Finished  Total 
Japan  1  -  1  2 
South Korea  18  5  -  23 
Note: As of December 2009 




4.  Differences in the Regulatory System 
 
4.1.  Japan - Two Pathways Exist 
 
Based on the discussion in the previous section, this section examines the regulatory system for 
market approval, especially in terms of conducting clinical trials. As described several times, market 
approval is required from the regulatory authority if drugs are to be introduced. In Japan, the MHLW 
bears this responsibility
24. In the review process for approval, clinical data are required. This data is 
collected  in  clinical  trials  that  are  conducted  according  to  the  standards  set  by  the  regulatory 
authority based on the Pharmaceutical Affairs Law (PAL)
25. This procedure for producing new drugs 
is basically universal. 
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These clinical trials are called chiken in Japan
26. The MHLW sets rules and procedures covering 
various matters in conducting chiken, from perspectives such as the protection of patients’ rights, 
maintaining safety, and keeping scientific quality and data reliability
27. When conducting chiken, a 
prior notification to the MHLW is required
28. The MHLW then investigates this for adequacy of 
content and gives instruction if necessary
29. 
 
Both the review for market approval and investigation for chiken are supposed to be carried out by 
the MHLW, but the Pharmaceuticals and Medical Devices Agency (PMDA) can also play the same 
role
30. The application and notification are, in fact, actually submitted to the PMDA. When receiving 
the  application  or  notification  from  an  applicant,  the  PMDA  will  conduct  necessary  review  or 
investigation,  and  reports  the  result  to  the  MHLW.  On  receiving  the  result,  the  MHLW  gives 
approval  after  consultation  with  the  Pharmaceutical  Affairs  and  Food  Sanitation  Council.  The 
PMDA is an independent administrative agency under the  MHLW,  and  is  considered to play a 
pivotal role as a regulatory authority in Japan concerning the review and investigation process. 
 
However, another pathway exists besides chiken for the administration to humans of unapproved 
new drugs. Doctors are supposed to conduct their medical practice under the Medical Practitioners 
Law (MPL)
31. A doctor’s act of producing unapproved drugs and administering them to patients is 
regarded as medical practice under the law, and so is not subject to PAL. This means such actions 
can be taken without the regulatory authority’s approval. When this is conducted as clinical research, 
the  head  of  the  clinical  research  organization  is  typically  required  to  issue  permission  with  the 
consent of the Internal Review Board set up within the organization based on the “Ethical Guideline 
for Clinical Research”
32. This action is then not incorporated into the strict framework of chiken. The 
guideline is just a guideline, and there is no legal obligation to follow it. 
 
As is clear from the above, there are two pathways through which clinical actions are conducted for 
the development of new drugs. One is chiken, or a clinical trial in which data is collected to obtain 
market approval in accordance with PAL. Another is clinical research conducted as medical practice 
under MPL. Of course the former pathway must be taken in order to launch a drug. The PMDA 
could conduct the investigation on the adequacy of the chiken, and so the PMDA also reviews data 
obtained from chiken for market approval. However, the PMDA will never take part in the clinical 
research conducted under MPL. 
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4.2.  Regenerative Medicine 
 
In addition to the usual procedure described in the previous subsection, additional procedures have 
been imposed for clinical trials on regenerative medicine based on the 1999 notice
33  issued by the 
MHLW. Specifically, “those who intend to commission the execution of chiken for medical devices 
using cells or tissue” are requested to acquire “confirmation on safety and quality from the MHLW 
prior to conducting chiken
34.” This action is called a confirmation application. The confirmation 
application is submitted to the PMDA, which reviews it based on the “Quality and safety assurance 




Even for clinical research not aiming at market approval, since 2006 additional procedures have 
been imposed on that which covers regenerative medicine. In clinical research in which “human 
stem cells are transplanted into the human body to treat disease,”
36  the head of the clinical research 
organization is required to hear the opinion of the MHLW based on the “Guidelines on Clinical 
Research Using Human Stem Cells (Guideline on Human Stem Cells)”
37. In the hearing process, the 
MHLW reviews the plan of the clinical research from a safety perspective based on Notification no. 
1314, as with the chiken by the PMDA
38. 
 
Clinical research reviewed by the MHLW based on the Guideline on Human Stem Cells, has only 
been conducted in 13 cases with 26 facilities
39  since September 2006 when the guideline went into 
force
40.  On  the  other  hand,  the  guideline  also states  that  it  “does not apply to clinical research 
already undertaken prior to the enforcement of the guideline,”
41  and more than 130 cases of clinical 
research have been conducted to date under the exemption
42. Much of this research currently being 
                                                         
33  Director-General, Pharmaceutical and Food Safety Bureau, MHLW (1999) 
34  Director-General, Pharmaceutical and Food Safety Bureau, MHLW (1999) 
35  Director-General, Pharmaceutical and Food Safety Bureau, MHLW (2000) 
36  Chapter 1 General Provisions, Section 3 Scope of Application 1, MHLW (2006) 
37  MHLW (2006) 
38  The case is in fact judged based on Annex 1 of Notification no. 1314, “Basic concepts for the handling and use of 
drugs and devices utilizing cells or tissues” and Annex 2, “Guidelines for assurance of quality and safety of drugs and 
devices processed from cells and tissues of human origin.” Regarding Annex 2, revised versions were issued in 
February 2008 (Director-General, Pharmaceutical and Food Safety Bureau, MHLW [2008a]) and September 2008 
(Director-General, Pharmaceutical and Food Safety Bureau, MHLW [2008b]). Consequently, Annex 2 of 
Notification no. 1314 has been abolished. 
39  As of November 2009 
40  http://www.nihs.go.jp/cgtp/cgtp/sec2/ct_prtcl/prtcl-j.html	  Last accessed on September 3, 2011 
41  Chapter 1 General rules, Paragraph 3 Scope, Details 1, Guidelines on Clinical Research Using Human Stem Cells 
42  http://www.nihs.go.jp/cgtp/cgtp/sec2/ct_prtcl/prtcl-j.html	    Last accessed on September 3, 2011 15 / 27 
 
conducted is considered to be performed this way
43. 
 
Clinical action concerning regenerative medicine is considered to require more rigorous examination 
than usual even if the purpose of the action is for regulatory approval or research as part of medical 
practice. The examination criteria for both are given in Notification no. 1314. However, a rigorous 
examination process was introduced in 1999 for clinical trials and in 2006 for clinical research. This 
represents a significant time lag. As previously mentioned, much of the research being performed 
uses the exemption. Moreover, the reviewer is different in each case. The PMDA is in charge of 
clinical trials, or chiken, and the MHLW covers clinical research; thus duplicate pathways remain. 
 
 
4.3.  South Korea 
 
The regulatory steps are basically the same in South Korea. South Korea’s regulatory authority for 
pharmaceutical  affairs  is  the  Korea  Food  and  Drug  Administration  (KFDA).  For  the  launch  of 
pharmaceuticals and medical devices, it is necessary to obtain the KFDA’s market approval after its 
review
44. RMPs are treated in the same manner. 
 
In the review process to obtain the KFDA’s market approval, data from the clinical trial are required. 
In conducting clinical trials, unapproved drugs are administered to humans. In South Korea, KFDA 
approval is also required for administration to humans of unapproved drugs
45. To this end, for the 
practice of clinical trials, application for an investigational new drug (IND) must be submitted to the 
KFDA, and its approval must be obtained in advance
46. 
 
The KFDA’s approval is also required for clinical research, which does not seek market approval 
directly, as long as unapproved drugs are administered to humans. In doing so, IND application is 
supposed  to  be  submitted  to  the  KFDA  as  in  clinical  trials.  There  are,  however,  two  kinds  of 
approval:  IND  approval  for  commercialization  aiming at market approval,  and  that  for research 
objectives. The rigor of the examination differs between the two
47. 
 
Behind the KFDA’s review for both clinical trial and clinical research is a fundamental belief that an 
                                                         
43  The Guidelines on Clinical Research Using Human Stem Cells was fully revised on November 1, 2010, and then 
the escape clause was deleted. 
44  Article 31, Korean Pharmaceutical Affairs Law 
45  Article 34, Korean Pharmaceutical Affairs Law 
46  Details of the review are given in KFDA (2009) and KFDA (2008). 
47  The same documents are basically required to be submitted for the application for research IND as those for that of 
commercial IND based on KFDA (2009). However, it is possible to simplify document submission for the application 
for research IND based on Article 7 of KFDA (2009). 16 / 27 
 
adequate examination must be necessary from the viewpoint of safety when unapproved drugs are 
administrated to humans
48. As mentioned, there are two types of approval. Approval for commercial 
IND is mainly applied for collecting the necessary data that are used for market approval. Approval 
for research IND is applied for research activities mainly conducted in clinical research institutes 
such as medical schools. Criteria differ according to each approval’s objectives. However, in terms 
of the act of administering unapproved drugs to humans, the activity plan, irrespective of the purpose, 
must go through review under the KFDA as a regulatory authority. 
 
 
4.4.  World Situation – Single Pathway 
 
It is clear from the above that the pathway to administer unapproved drugs to humans is unique in 
South Korea. Comparing the regulatory frameworks of Japan and South Korea, a large difference 
can be cited in this regard. Though differences exist among major countries such as the United States 
and EU member countries in the details of their regulations, it is almost the same that regulatory 
approval by the authorities is required when unapproved drugs are administered to humans in any 
clinical research, as well as clinical trials
49. 
 
Based on the above discussion, Figure 4 shows a conceptual framework of regulations for RMPs in 
Japan and South Korea. 
 
                                                         
48  Based on an interview with a KFDA reviewer 
49  In the United States, application for IND is required to the regulatory authority when administrating unapproved 
drugs to human. This follows a series of legal actions such as the Kefauver-Harris Amendment established in 1962. 
In Europe, the EU clinical trials directive (Directive 2001/20/EC of the European Parliament and the Council of 4 
April 2001 on the approximation of the laws, regulations and administrative practice in the conduct of clinical trials 
on medicinal products for human use) was issued in 2001, in which the initiation of clinical trials requires an 
approval from the regulatory authority. EU member countries are aiming to achieve implementation of domestic 
measures for the directive. Not only clinical trials for the purpose of regulatory approval but any type of clinical trial 
such as non-commercial is subject to such legal actions in the US and European countries. 17 / 27 
 
 




5.  What Happens 
 
5.1.  University as a Main Player in Clinical Research 
 
As seen before, Japan has actively promoted research aimed at commercialization of regenerative 
medicine. In terms of research output, Japan is number three in the world after the United States and 
Europe. As described in subsection 3.2, many papers have been published in the category of applied 
research in Japan, which means there may be a certain amount of clinical research being conducted 
there. 
 
Table 3 shows the attributes of the top 50 organizations according to the number of papers published 
in the field of regenerative medicine. Most of these organizations are universities, with a small 
representation by public research institutes. Companies do not appear. This can be understood as a 
reflection of the characteristics of regenerative medicine, as described in section 2, in that it is based 
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Table 3    Attributes of World’s Top 50 Institutes for Regenerative Medicine 




US  19  1  20 
Japan  11    11 
Europe  7  2  9 
China  5    5 
South 
Korea 
3    3 
Others  3    3 
Source: Based on data from JPO (2009) 
 
On the other hand, the commercialization of regenerative medicine, which means providing RMPs to 
the  market  after  receiving  market  approval  from  the  regulatory  authority,  is  expected  to  be 
conducted by the private sector. It can therefore be said that clinical trials under the regulatory 
legislation are connecting these universities with the private sector as well as connecting these two 
stages. As we have seen, however, only a small number of clinical trials on regenerative medicine 
have been conducted thus far in Japan, and it is hard to say the two are smoothly connected. 
 
Focusing on details of the regulatory system in Japan with the understanding discussed above, a 
critical fact is found  in  that clinical trials  and clinical research are  conducted under completely 
different regulatory systems. Unlike the rest of the world, Japan has two pathways for administering 
unapproved drugs to humans for the development of new drugs including RMPs. Another important 
fact we find is that clinical research is not connected to clinical trials in Japan. The question then is 
how the existence of the two pathways affects this fact. 
 
 
5.2.  Duplex Pathways Unconnected 
 
As  noted  above,  most  of  the  organizations  conducting  research  on  regenerative  medicine  are 
universities. This situation is common to the United States, Europe, South Korea, and Japan. In an 
institute like a university, the researcher’s motive is to publish the research results in an academic 
paper. The activity is of course underpinned by the hopes  that  the  new  therapy will eventually 
become widespread and used to help patients. 
 
In  clinical  research,  the  administration  of  unapproved  drugs  to  humans  is  naturally  practiced. 19 / 27 
 
Clinical institutes  will apply to the regulatory authority for permission of  the act if approval is 
necessary, and the regulatory authority will issue approval after due examination. In the examination 
process, the regulatory authority comprehends the specific case and requests changes to the research 
plan if necessary. Conversely, an application is not made if these procedures are not required for the 
system. As a result, the regulatory authority will have no comprehension of the clinical research 
being conducted. 
 
This  situation  has  only  recently  emerged.  In  Japan,  as  mentioned  above,  clinical  research 
organizations such as universities do not need to submit applications or acquire approval from the 
regulatory authority in their practice of clinical research. As a result, despite being quite similar in 
terms of administering unapproved drugs to humans, clinical research and clinical trials are regarded 
as completely different acts under different systems and neither will be systematically related. 
 
For regenerative medicine, and in comparison with drugs and medical devices, the need to connect 
research to clinical trials is also relatively low for clinical research organizations given the technical 
characteristics.  It  is  very  difficult  for  clinical  research  organizations  to  themselves  manufacture 
drugs  that  consist  mainly  of  chemical  compounds  and  medical  devices  that  have  a  mechanical 
structure. Therefore, collaboration with outside companies is necessary to enable manufacturing and 
the provision of drugs and medical devices to the organization. This type of cooperation is expected 
to have a direct link with clinical trials by companies seeking to commercialize drugs or medical 
devices. 
 
Clinical research organizations can manufacture RMPs relatively easily. Typical examples are RMPs 
with low degrees of cell processing that are manufactured within clinical research organizations as a 
medical practice and administered to humans for treatment. Clinical organizations can also readily 
manufacture  well-organized  RMPs  through  various  degrees  of  tissue  engineering,  in  contrast  to 
manufacturing of drugs’ chemical compounds and medical devices’ mechanical structures. Thus it 
becomes  common  for  clinical  organizations  to  manufacture  RMPs  by  themselves  without  the 
involvement  of  external  companies  and  administer  them  to  humans.  Therefore  there  are  few 
expectations of related clinical trials by external companies. 
 
 
5.3.  J-TEC – Approved with Only Two Cases 
 
In light of the items discussed in the previous subsection, we can examine the actual case of the 
autologous cultured epidermis by J-TEC named JACE. This is the only case to receive approval in 20 / 27 
 
Japan as an RMP. Table 4 outlines this approval. Remarkably, there were only two patients in the 
clinical trials. This low number of cases prompted significant debate, not only in the examination of 
regulatory approval, but even in the post-approval review of insurance coverage. 
 
Table 4    Outline of Market Approval for JACE 
Adaptable Case 
Extensive severe burns with no donor area 
obtained  for  autologous  skin  grafting,  as 
well as over 30% of the total body surface 




Multicenter uncontrolled open-label trial 
Number of Cases  2 
Approval 
Condition 
Post-market  clinical  trial  (10  cases)  and 
drug use survey on all patients 
Fast Track  Yes 
Source: Created by the authors based on PMDA (2007), etc. 
 
Regulatory approval is deliberated in the Pharmaceutical and Food Sanitation Council in the MHLW 
after  the  PMDA  examination,  and  eventually  goes  through  the  MHLW approval process
50.  The 
published minutes suggest there was discussion about the number of clinical cases. Clearly doubt 
was  raised  about  approval  with  such  a  small  number.  Responding  to  this  doubt  the  Council 
secretariat,  which  is  served  by  the  MHLW,  replied  that  this  was  a  “very  special  case”  and  a 
post-market clinical trial was mandated
51. 
 
The lack of cases can also be considered as influencing the discussion on whether medical insurance 
will  cover  the  product.  Medical  insurance  finally  became  applicable  for  JACE  under  certain 
conditions. Coverage is limited to treatment practiced only in facilities that meet certain criteria. 
Moreover, a detailed record of the patient’s condition must be attached to a reimbursement claim
52. 
 
After winning regulatory approval, it took about a year and a half for JACE to become applicable 
under  medical  insurance,  in  contrast  to  the  usual  six  months.  The  Japan  Medical  Association’s 
                                                         
50  In fact, the deliberation is supposed to take place in the Subcommittee on Medical Devices and In Vitro 
Diagnostics under the Pharmaceutical and Food Sanitation Council. 
51  Minutes of the Subcommittee on Medical devices and In Vitro Diagnostics, Pharmaceutical and Food Sanitation 
Council, August 23, 2007 
52  Minutes of the General Meeting of the Central Social Insurance Medical Council, December 17, 2008 21 / 27 
 
Questionable Interpretation Committee was said to have been reluctant to apply medical insurance 




The constraints imposed on insurance coverage as well as the delay in insurance applicability created 
significant economic loss for J-TEC
54. The presence of only two patients in clinical trials not only 
created a difficult approval for the MHLW, but also had a large impact on the business of J-TEC. 
 
 
5.4.  Clinical Research Unutilized 
 
A question that is naturally raised is whether other clinical cases use the same technique as JACE in 
Japan. JACE is a Green-type autologous cultured epidermis
55. Feeder cells have been transferred by 
Howard  Green,  the  developer
56.  A  great  deal  of  clinical  research  in  Japan  uses  a  Green-type 
autologous cultured epidermis, reportedly the same as that of J-TEC. In the clinical research lead by 
the Department of Dental Surgery in the School of Medicine at Nagoya University, since 1995 more 
than 80 cases of using Green-type autologous cultured epidermis have been reported by six clinical 
organizations
57.  Since  1985  more  than  550  cases  of  Green-type  autologous  transplantation  of 
epidermis  have  also  been  carried  out in  the  Department  of  Plastic  Surgery  of  the  St.  Marianna 
University School of Medicine (in Kanagawa, Japan)
58,59. 
 
While  there  have  been  many  clinical  cases,  the  PMDA’s  review  report  on  JACE  mentions  no 
specific information on any of them. The report notes questions and answers between the PMDA and 
J-TEC  regarding  efficacy  and  safety  of  JACE.  It  states  that  JACE  is  a  “Green-type  autologous 
cultured epidermis developed under technology transfer from Department of Dental Surgery, School 
of Medicine, Nagoya University [omitted] manufacturing process is not identical but similar [to 
Nagoya  University]
60.”  Meanwhile,  there  is  not  mention  of  the  80  clinical  cases  at  Nagoya 
University. Of course, there is no reference to the cases at the St. Marianna University School of 
Medicine either. 
 
                                                         
53  Nikkei Biotechnology & Business issued June 2, 2008, p. 13 
54  Nikkei Biotechnology & Business issued October 26, 2009, p. 13 
55  Cultured epidermis using mouse embryo-derived cells as a feeder developed by Green et al. of Harvard University 
in 1975 is generally called “Green-type cultured epidermis.” 
56  http://www.jpte.co.jp/business/regenerative/cultured_epidermis.html 
57  Ueda, M., Sumi, Y., Mizuno, H. and Hata, K. (1998) 
58  http://www.marianna-u.ac.jp/hospital/sinryou/shinryouka_20.html    Last accessed on September 3, 2011 
59  http://www.jpte.co.jp/business/regenerative/interviews.html    Last accessed on September 3, 2011 
60  PMDA (2007) 22 / 27 
 
Clinical research results were not utilized in the examination at all, and it is of course obvious that 
data obtained in the clinical research were not used in the regulatory reviewing process. Such results 
are not from clinical trials in which every procedure must meet a strict protocol set by the regulatory 
authority but from clinical research in which no legal framework is imposed. Yet still, why was there 
no reference? Also, why is there no collaboration between J-TEC and Nagoya University or St. 
Marianna University in conducting J-TEC’s clinical trial even though J-TEC has introduced the 




It is difficult to answer these questions directly. First it must be said the PMDA is not in a position to 
grasp the situation of clinical research being conducted, and there are no measures for acquiring 
comprehensive information on clinical research. The framework of clinical research, not clinical 
trials, is also said to be enough for Nagoya University and St. Marianna University to practice 
clinical application of their research under Japan’s regulatory system as long as they are clinical 
organizations. There is no need or motivation to deliberately work with a framework of time- and 
effort-consuming clinical trials. The concept described in subsection 5.2 may give a clear example of 
Japan’s only approved RMP. 
 
Under these circumstances, it seems that it was extremely difficult for J-TEC to accumulate clinical 
cases and the PMDA had no choice but to give approval with only two cases in clinical trials. Amid 
the government’s high expectations for regenerative medicine was the desire to see specific results. 
This may have placed strong pressure on the PMDA to give early approval, thus approval was given 
with the conditions of a drug use survey on all patients and 10 cases of post-market clinical trials. 
The granting of approval for JACE could be seen as a consequence of the PMDA’s best efforts 




6.  Conclusion - The Ideal Climate 
 
6.1.  Exit for Second Pathway 
 
Japan’s medical system provides an exit of diffusing and utilizing the fruits of clinical research for 
patients. This exit is considered to be not the launch of an RMP but rather the dissemination of 
regenerative medicine as a self-contained medical practice conducted within a clinical organization. 
                                                         
61  http://www.jpte.co.jp/business/regenerative/interviews.html    Last accessed on September 3, 2011 23 / 27 
 
This  exit  comes  down  to  implementation  of  a  clinical  organization-based  treatment  under  the 
“advanced  medical  therapy”  system.  In  this  system,  the  clinical  organization  certified  by  each 
advanced therapy can practice the therapy in combination with other therapies already covered by 
medical insurance. Otherwise, even insurance-covered therapies will not be covered under Japan’s 
medical  insurance  system  if  practiced  in  combination  with  uncovered  advanced  therapies.  This 
system is said to be the exit for the second pathway. 
 
The primary focus of the advanced medical therapy system is not on products such as RMPs but on 
medical techniques. This pathway is expected to play a role in terms of dissemination for therapy 
that  will  not  necessarily  require  RMPs  during  its  practice.  Regenerative  medicine,  however, 
generally requires RMPs for its treatment. Even if regenerative medicine becomes subject to the 
advanced medical therapy system, the supply of RMPs, namely the series of cell processing, is 
supposed to be practiced by medical doctors within clinical organizations under the system. 
 
In this process, cell isolation, culturing and processing are purely an engineering operation that will 
never come into contact with patients. Non-medical practices based on both hard and soft aspects are 
needed. These include facility preparation in terms of ensuring safety to minimize the risk of viral 
infection,  implementation  of  appropriate  management  and  placement  of  personnel  with  cell 
treatment skill. It is difficult for each clinical research organization and even medical institutions to 
prepare these aspects independently. This situation is not efficient from the viewpoint of allocation 
of limited medical resources. 
 
For dissemination of regenerative medicine, it must be realistic to commercialize RMPs outside the 
medical  organization  and  supply  them  to  the  medical  arena
62.  In  other  words,  it  is  not  easy  to 
disseminate  regenerative  medicine  if  following  the  second  pathway  leads  to  self-contained 
implementation as a medical practice within medical facilities. 
 
 
6.2.  Solution Required - Integration of Pathways 
 
The  dissemination  of  regenerative  medicine  to  society  requires  going  through  the  first  pathway 
shown in Figure 7. While much of the clinical research on regenerative medicine has no clear exit, 
there is a strong requirement to connect its output with the exit as a product launch for dissemination. 
Cases conducted by the Nagoya University School of Medicine and St. Marianna University School 
of Medicine are seen as positive, individual initiatives, they have not yet achieved an RMP launch. 
                                                         
62  For further perspective, see Kurata, K. (2009). 24 / 27 
 
The therapy is practiced only within the universities and related clinical organizations, and there is 
no spread in terms of technology diffusion. 
 
While a certain amount of public funding is invested in clinical research activities and considerable 
output has resulted, Japan’s regulatory system with two pathways is barely effective in leading the 
output to the commercialization on RMPs’ supply and dissemination of regenerative medicine. A 
valuable opportunity for clinical research is not utilized in launching RMPs. A solution is needed in 
which  the  regulatory  system  works  and  promotes  dissemination  of  regenerative  medicine.  The 
PMDA as a regulatory authority needs to review clinical research as well as clinical trials. To realize 
this, the two pathways need to be integrated like in other major countries. From the viewpoint of 
returning output from public funding to the public and improving human welfare, this is an urgent 
issue. 
 
The regulatory framework for pharmaceutical affairs is a complex system with a variety of factors at 
play. It will be necessary to increase the number of reviewers in the PMDA if the PMDA is to play a 
new role of reviewing clinical research. Otherwise, there is the possibility of increased time for 
market approval, for which the PMDA is criticized even now. The topics discussed in this paper are 
only  part  of  the  complex  system,  and  the  discussion  is  incomplete.  Considering  the  status  of 
introduction of regenerative medicine in Japan and countries such as South Korea, the measures 
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